董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Philippe Schaison | 男 | Director | 64 | 8.48万 | 未持股 | 2025-10-30 |
| Desiree Gruber | 女 | Director | 57 | 16.50万 | 未持股 | 2025-10-30 |
| Michelle Kerrick | 女 | Director | 62 | 18.25万 | 18.98 | 2025-10-30 |
| Brian Miller | 男 | Director | 50 | 17.00万 | 3360.38 | 2025-10-30 |
| Doug Schillinger | 男 | Director | 51 | 27.23万 | 21.60 | 2025-10-30 |
| Pedro Malha | 男 | President, Chief Executive Officer and Director | 53 | 631.13万 | 未持股 | 2025-10-30 |
| Philippe Schaison | 男 | Director | -- | 未披露 | 未持股 | 2025-10-30 |
| Stephen J. Fanning | 男 | Director | 73 | 17.50万 | 52.73 | 2025-10-30 |
| Brenton L. Saunders | 男 | Chairman of the Board | 55 | 25.75万 | 1065.78 | 2025-10-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sheri Lewis | 女 | Chief Supply Chain and Operations Officer | 59 | 222.66万 | 30.95 | 2025-10-30 |
| Michael Monahan | 男 | Chief Financial Officer | 53 | 252.61万 | 68.51 | 2025-10-30 |
| Ron Menezes | 男 | Chief Revenue Officer | 62 | 219.11万 | 未持股 | 2025-10-30 |
| Pedro Malha | 男 | President, Chief Executive Officer and Director | 53 | 631.13万 | 未持股 | 2025-10-30 |
董事简历
中英对照 | 中文 | 英文- Philippe Schaison
-
Philippe Schaison自2015年3月起担任Allergan Medical的执行副总裁兼总裁。此前，Schaison先生自2013年9月起担任 U.S. Medical of Allergan, Inc. d 公司副总裁兼总裁。在加入 Allergan, Inc.之前， Schaison在Clarins担任过多个领导职位，包括全球旅游零售的全球总裁；拉丁美洲和中东、非洲的总裁；并担任执行委员会的成员。他曾担任Aesthetic Factors（一家美学创业公司）的首席执行官； Johnson & Johnson全球皮肤护理的副总裁；在L’Oreal 领先的南欧，中东和印度，Vichy L’Oreal美国和希腊担任各个总经理职位；担任Arthur D. Little Consulting Philadelphia美国医疗保健实践的领导者；以及Merck & Co. 的多个销售和营销职位。Philippe也是Galien Foundation的董事会成员，该基金会负责监督和指导Prix Galien在美国的活动，该奖项被视为相当于生物制药研究的诺贝尔奖。他拥有Hautes Etudes Commerciales（H.E.C。）的工商管理硕士学位和Université de Paris V。的 药学博士学位。
Philippe Schaison was appointed as Chief Executive Officer Syneron Candela North America and Global Executive Vice President Strategy and Business Development in November 2016. Before joining Syneron, Dr. Schaison served as President of Allergan U.S. Aesthetic and Dermatology and was a member of the Allergan Executive Leadership Team. Before joining Allergan in 2013 Dr. Schaison served as President, World Wide Travel Retail & Regional President, LATAM and MEA, at Clarins in New York from 2010 to 2013. From 2008 to 2010 Dr. Schaison served as CEO for Aesthetic Factors, a manufacturer of point-of-care systems for regenerative medicines. From 2003 to 2008 Dr. Schaison served as Vice President of Global Skin Care for Johnson & Johnson. Prior to joining Johnson & Johnson, Dr. Schaison worked in executive positions at L'Oréal from 1997 to 2003. Dr. Schaison started his professional career at Merck & Company as a Group Manager in Paris. He is a Board Member of the Galien Foundation, New York. Dr. Shaison earned an MBA Marketing from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy (Industrial) from the University of Paris. - Philippe Schaison自2015年3月起担任Allergan Medical的执行副总裁兼总裁。此前，Schaison先生自2013年9月起担任 U.S. Medical of Allergan, Inc. d 公司副总裁兼总裁。在加入 Allergan, Inc.之前， Schaison在Clarins担任过多个领导职位，包括全球旅游零售的全球总裁；拉丁美洲和中东、非洲的总裁；并担任执行委员会的成员。他曾担任Aesthetic Factors（一家美学创业公司）的首席执行官； Johnson & Johnson全球皮肤护理的副总裁；在L’Oreal 领先的南欧，中东和印度，Vichy L’Oreal美国和希腊担任各个总经理职位；担任Arthur D. Little Consulting Philadelphia美国医疗保健实践的领导者；以及Merck & Co. 的多个销售和营销职位。Philippe也是Galien Foundation的董事会成员，该基金会负责监督和指导Prix Galien在美国的活动，该奖项被视为相当于生物制药研究的诺贝尔奖。他拥有Hautes Etudes Commerciales（H.E.C。）的工商管理硕士学位和Université de Paris V。的 药学博士学位。
- Philippe Schaison was appointed as Chief Executive Officer Syneron Candela North America and Global Executive Vice President Strategy and Business Development in November 2016. Before joining Syneron, Dr. Schaison served as President of Allergan U.S. Aesthetic and Dermatology and was a member of the Allergan Executive Leadership Team. Before joining Allergan in 2013 Dr. Schaison served as President, World Wide Travel Retail & Regional President, LATAM and MEA, at Clarins in New York from 2010 to 2013. From 2008 to 2010 Dr. Schaison served as CEO for Aesthetic Factors, a manufacturer of point-of-care systems for regenerative medicines. From 2003 to 2008 Dr. Schaison served as Vice President of Global Skin Care for Johnson & Johnson. Prior to joining Johnson & Johnson, Dr. Schaison worked in executive positions at L'Oréal from 1997 to 2003. Dr. Schaison started his professional career at Merck & Company as a Group Manager in Paris. He is a Board Member of the Galien Foundation, New York. Dr. Shaison earned an MBA Marketing from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy (Industrial) from the University of Paris.
- Desiree Gruber
-
Desiree Gruber自2020年10月起担任我们的董事之一。她创立了Full Picture，并自成立以来一直担任首席执行官，该公司是一家品牌加速器，内容生产，沟通和咨询服务公司，现已成立21年，她热衷于帮助客户更有效地讲述他们的故事，并向世界推出新想法。作为一名企业家、商业战略家和风险投资家，格鲁伯继续推进她的使命，即塑造时代精神的关键时刻，并重新构想品牌如何让全球受众在她的工作中感到愉悦和参与。通过DGNL，格鲁伯在培养和支持女性创始人和高管方面发挥了卓越的作用。DGNL的目标是为女性创造真正的机会，让她们获得可衡量的成功，DGNL投资并设计了消费者、技术和媒体领域的转型交易，以建立女性赋权的遗产。迄今为止，格鲁伯的许多成就包括与人共同创办了《天桥骄子》电视连续剧。除了获得皮博迪奖外，作为这部开创性的剧集的执行制片人，她已经连续16季获得GLAAD媒体奖，并获得了14项艾美奖提名，她毕生都在倡导一个更公平、更包容的世界，她自豪地担任联合国儿童基金会美国分部的董事会成员，以及我们所传递的上帝之爱，并获得了联合国儿童基金会2018年的同情精神奖。她还是Anthos Capital、Pharrell Williams’Something in the Water和Chegg等领先组织的顾问。
Desiree Gruber has served as one of our directors since October 2020. She founded and has been the Chief Executive Officer since inception of Full Picture, a brand accelerator, content production, communications, and consulting services company now in its 21st year, with a passion to help her clients more effectively tell their stories and launch new ideas into the world. Ms. Gruber continues to evolve her mission of shaping zeitgeist-defining moments and reimagining how brands delight and engage global audiences in her work as an entrepreneur, business strategist, and venture capitalist.Through DGNL, Ms. Gruber has embraced a preeminent role in developing and supporting female founders and C-suite executives. With a goal of creating real opportunities for women to achieve measurable success, DGNL invests in and architects transformational deals across the consumer, technology, and media spectrum in order to establish a legacy of female empowerment.Among Ms. Gruber's many accomplishments to date is co-founding the Project Runway television series. In addition to her Peabody Award, as executive producer of the groundbreaking show for 16 seasons she has received a GLAAD Media Award and earned 14 Emmy nominations.A lifelong advocate for a more equitable and inclusive world, she proudly serves on the boards of UNICEF USA, Tech:NYC, and God's Love We Deliver, and was the recipient of UNICEF's 2018 Spirit of Compassion Award. She is also an advisor to leading organizations such as Anthos Capital, Pharrell Williams' Something in the Water and Chegg. - Desiree Gruber自2020年10月起担任我们的董事之一。她创立了Full Picture，并自成立以来一直担任首席执行官，该公司是一家品牌加速器，内容生产，沟通和咨询服务公司，现已成立21年，她热衷于帮助客户更有效地讲述他们的故事，并向世界推出新想法。作为一名企业家、商业战略家和风险投资家，格鲁伯继续推进她的使命，即塑造时代精神的关键时刻，并重新构想品牌如何让全球受众在她的工作中感到愉悦和参与。通过DGNL，格鲁伯在培养和支持女性创始人和高管方面发挥了卓越的作用。DGNL的目标是为女性创造真正的机会，让她们获得可衡量的成功，DGNL投资并设计了消费者、技术和媒体领域的转型交易，以建立女性赋权的遗产。迄今为止，格鲁伯的许多成就包括与人共同创办了《天桥骄子》电视连续剧。除了获得皮博迪奖外，作为这部开创性的剧集的执行制片人，她已经连续16季获得GLAAD媒体奖，并获得了14项艾美奖提名，她毕生都在倡导一个更公平、更包容的世界，她自豪地担任联合国儿童基金会美国分部的董事会成员，以及我们所传递的上帝之爱，并获得了联合国儿童基金会2018年的同情精神奖。她还是Anthos Capital、Pharrell Williams’Something in the Water和Chegg等领先组织的顾问。
- Desiree Gruber has served as one of our directors since October 2020. She founded and has been the Chief Executive Officer since inception of Full Picture, a brand accelerator, content production, communications, and consulting services company now in its 21st year, with a passion to help her clients more effectively tell their stories and launch new ideas into the world. Ms. Gruber continues to evolve her mission of shaping zeitgeist-defining moments and reimagining how brands delight and engage global audiences in her work as an entrepreneur, business strategist, and venture capitalist.Through DGNL, Ms. Gruber has embraced a preeminent role in developing and supporting female founders and C-suite executives. With a goal of creating real opportunities for women to achieve measurable success, DGNL invests in and architects transformational deals across the consumer, technology, and media spectrum in order to establish a legacy of female empowerment.Among Ms. Gruber's many accomplishments to date is co-founding the Project Runway television series. In addition to her Peabody Award, as executive producer of the groundbreaking show for 16 seasons she has received a GLAAD Media Award and earned 14 Emmy nominations.A lifelong advocate for a more equitable and inclusive world, she proudly serves on the boards of UNICEF USA, Tech:NYC, and God's Love We Deliver, and was the recipient of UNICEF's 2018 Spirit of Compassion Award. She is also an advisor to leading organizations such as Anthos Capital, Pharrell Williams' Something in the Water and Chegg.
- Michelle Kerrick
-
Michelle Kerrick，自2021年5月4日起担任董事会成员。Kerrick女士曾担任国际专业服务公司德勤洛杉矶办事处的西部地区市场负责人和管理合伙人。Kerrick女士在德勤工作了35年，于2020年9月退休。Kerrick女士在其职位上负责推动全国战略以及西部13个办事处和洛杉矶办事处的客户和业务增长以及战略定位。Kerrick女士拥有超过35年的专业经验，曾服务于多个行业领域的多元化上市公司和私营公司，从中型市场公司到大型跨国公司。Kerrick女士在财务和会计、风险管理和公司治理方面具有专长。Kerrick女士是AMH、F.K.a. American Homes 4 Rent以及Capital Group子公司Capital银行 & Trust Company的独立公司董事会董事。Kerrick女士是加利福尼亚州和亚利桑那州会计委员会和美国注册会计师协会的退休成员。
Michelle Kerrick,has served on Board of Directors since May 4, 2021. Ms. Kerrick served as the West Region Market Leader and Managing Partner of the Los Angeles office of Deloitte, an international professional services firm. Ms. Kerrick worked at Deloitte for 35 years before retiring in September 2020. In her role, Ms. Kerrick was responsible for driving national strategy and client and business growth and strategic positioning across the 13-office West Region and the Los Angeles office. With more than 35 years of professional experience, Ms. Kerrick has served a diverse group of publicly and privately held companies, ranging from middle-market companies to large multi-nationals, in various industry sectors. Ms. Kerrick has expertise in finance and accounting, risk management and corporate governance. Ms. Kerrick is an independent corporate board director for AMH, f.k.a. American Homes 4 Rent, and Capital Bank & Trust Company, a subsidiary of the Capital Group. Ms. Kerrick is a retired member of the California and Arizona State Board of Accountancy and the American Institute of Certified Public Accountants. - Michelle Kerrick，自2021年5月4日起担任董事会成员。Kerrick女士曾担任国际专业服务公司德勤洛杉矶办事处的西部地区市场负责人和管理合伙人。Kerrick女士在德勤工作了35年，于2020年9月退休。Kerrick女士在其职位上负责推动全国战略以及西部13个办事处和洛杉矶办事处的客户和业务增长以及战略定位。Kerrick女士拥有超过35年的专业经验，曾服务于多个行业领域的多元化上市公司和私营公司，从中型市场公司到大型跨国公司。Kerrick女士在财务和会计、风险管理和公司治理方面具有专长。Kerrick女士是AMH、F.K.a. American Homes 4 Rent以及Capital Group子公司Capital银行 & Trust Company的独立公司董事会董事。Kerrick女士是加利福尼亚州和亚利桑那州会计委员会和美国注册会计师协会的退休成员。
- Michelle Kerrick,has served on Board of Directors since May 4, 2021. Ms. Kerrick served as the West Region Market Leader and Managing Partner of the Los Angeles office of Deloitte, an international professional services firm. Ms. Kerrick worked at Deloitte for 35 years before retiring in September 2020. In her role, Ms. Kerrick was responsible for driving national strategy and client and business growth and strategic positioning across the 13-office West Region and the Los Angeles office. With more than 35 years of professional experience, Ms. Kerrick has served a diverse group of publicly and privately held companies, ranging from middle-market companies to large multi-nationals, in various industry sectors. Ms. Kerrick has expertise in finance and accounting, risk management and corporate governance. Ms. Kerrick is an independent corporate board director for AMH, f.k.a. American Homes 4 Rent, and Capital Bank & Trust Company, a subsidiary of the Capital Group. Ms. Kerrick is a retired member of the California and Arizona State Board of Accountancy and the American Institute of Certified Public Accountants.
- Brian Miller
-
Brian Miller，自2021年5月4日起在董事会任职。Miller先生是私募股权公司Linden Capital Partners LLC（“Linden”）的联合创始人和合伙人，该公司成立于2004年。自1998年起参与医疗保健本金投资。在加入Linden之前，Miller先生是私募股权公司First Chicago Equity Capital的医疗保健团队的创始成员。Miller先生的职业生涯始于所罗门兄弟公司（现为花旗集团）的投资银行部门。他目前是Lifestyles Healthcare、Vital Care、Formulated Solutions、MeriCal、StatLab Medical Products和Regenity的董事会成员，之前是Z-Medica、Solara、SeraCare、BarrierSafe Solutions International、CORPAK MedSystems、HYCOR Biomedical、Strata Pathology Services、Flexan和Suture Express的董事会成员。他是AdvaMed的董事会成员，医疗保健私募股权协会的创始人，芝加哥私募股权分析师的创始人，芝加哥大学医学中心的受托人，芝加哥经济俱乐部的成员。
Brian Miller,has served on Board of Directors since May 4, 2021. Mr. Miller is the Co-Founder and Partner of Linden Capital Partners LLC ("Linden"), a private equity firm, which was founded in 2004. He has been involved in healthcare principal investing since 1998. Prior to Linden, Mr. Miller was a founding member of the healthcare team at First Chicago Equity Capital, a private equity firm. Mr. Miller began his career in the investment banking division of Salomon Brothers Inc. (currently Citigroup). He is currently a board member of Lifestyles Healthcare, Vital Care, Formulated Solutions, MeriCal, StatLab Medical Products and Regenity, and was previously a board member of Z-Medica, Solara, SeraCare, BarrierSafe Solutions International, CORPAK MedSystems, HYCOR Biomedical, Strata Pathology Services, Flexan, and Suture Express. He is a board member of AdvaMed, the Founder of the Healthcare Private Equity Association, the founder of Private Equity Analysts of Chicago, a Trustee of The University of Chicago Medical Center, and a member of the Economic Club of Chicago. - Brian Miller，自2021年5月4日起在董事会任职。Miller先生是私募股权公司Linden Capital Partners LLC（“Linden”）的联合创始人和合伙人，该公司成立于2004年。自1998年起参与医疗保健本金投资。在加入Linden之前，Miller先生是私募股权公司First Chicago Equity Capital的医疗保健团队的创始成员。Miller先生的职业生涯始于所罗门兄弟公司（现为花旗集团）的投资银行部门。他目前是Lifestyles Healthcare、Vital Care、Formulated Solutions、MeriCal、StatLab Medical Products和Regenity的董事会成员，之前是Z-Medica、Solara、SeraCare、BarrierSafe Solutions International、CORPAK MedSystems、HYCOR Biomedical、Strata Pathology Services、Flexan和Suture Express的董事会成员。他是AdvaMed的董事会成员，医疗保健私募股权协会的创始人，芝加哥私募股权分析师的创始人，芝加哥大学医学中心的受托人，芝加哥经济俱乐部的成员。
- Brian Miller,has served on Board of Directors since May 4, 2021. Mr. Miller is the Co-Founder and Partner of Linden Capital Partners LLC ("Linden"), a private equity firm, which was founded in 2004. He has been involved in healthcare principal investing since 1998. Prior to Linden, Mr. Miller was a founding member of the healthcare team at First Chicago Equity Capital, a private equity firm. Mr. Miller began his career in the investment banking division of Salomon Brothers Inc. (currently Citigroup). He is currently a board member of Lifestyles Healthcare, Vital Care, Formulated Solutions, MeriCal, StatLab Medical Products and Regenity, and was previously a board member of Z-Medica, Solara, SeraCare, BarrierSafe Solutions International, CORPAK MedSystems, HYCOR Biomedical, Strata Pathology Services, Flexan, and Suture Express. He is a board member of AdvaMed, the Founder of the Healthcare Private Equity Association, the founder of Private Equity Analysts of Chicago, a Trustee of The University of Chicago Medical Center, and a member of the Economic Club of Chicago.
- Doug Schillinger
-
Doug Schillinger，自2021年5月4日起担任董事会成员。Schillinger先生于2004年加入DW Healthcare Partners，目前担任董事总经理，负责监督该公司的多项投资组合。Schillinger先生的投资、交易和董事会经验包括范围广泛的医疗保健服务和医疗器械，包括制药服务、诊断、医疗技术产品和设备、供应商服务、实验室服务、急性后护理、医疗美容和远程医疗。在加入DW Healthcare Partners之前，Schillinger先生曾任职于贝恩公司和埃森哲（前身为Andersen Consulting）。他目前是Public Partnerships Limited、Parnell Veterinary Pharmaceuticals、Aequor Healthcare Services、Chrysalis、CareXM和Vets Plus Inc.的董事会成员。Schillinger先生此前曾是Z-Medica、Reliant Rehabilitation、Tandem Labs、American Optics、Global Physics Solutions、Spectrum Solutions和Arteriocyte Medical Systems的董事会成员。Schillinger先生也是医疗保健私募股权协会的现任董事会成员和哈佛商学院校友董事会的前任成员。
Doug Schillinger,has served on Board of Directors since May 4, 2021. Mr. Schillinger joined DW Healthcare Partners in 2004 and is currently a Managing Director and oversees several of the firm's portfolio investments. Mr. Schillinger's investment, transaction and board experience include a broad array of healthcare service and medical devices including pharma services, diagnostics, medical tech products and devices, provider services, laboratory services, post-acute care, medical aesthetics, and telehealth. Before joining DW Healthcare Partners, Mr. Schillinger worked for Bain & Company and Accenture (previously Andersen Consulting). He is currently a board member of Public Partnerships Limited, Parnell Veterinary Pharmaceuticals, Aequor Healthcare Services, Chrysalis, CareXM, and Vets Plus Inc. Mr. Schillinger was previously a board member of Z-Medica, Reliant Rehabilitation, Tandem Labs, American Optics, Global Physics Solutions, Spectrum Solutions, and Arteriocyte Medical Systems. Mr. Schillinger is also a current board member of the Healthcare Private Equity Association and a former member of the Harvard Business School Alumni Board of Directors. - Doug Schillinger，自2021年5月4日起担任董事会成员。Schillinger先生于2004年加入DW Healthcare Partners，目前担任董事总经理，负责监督该公司的多项投资组合。Schillinger先生的投资、交易和董事会经验包括范围广泛的医疗保健服务和医疗器械，包括制药服务、诊断、医疗技术产品和设备、供应商服务、实验室服务、急性后护理、医疗美容和远程医疗。在加入DW Healthcare Partners之前，Schillinger先生曾任职于贝恩公司和埃森哲（前身为Andersen Consulting）。他目前是Public Partnerships Limited、Parnell Veterinary Pharmaceuticals、Aequor Healthcare Services、Chrysalis、CareXM和Vets Plus Inc.的董事会成员。Schillinger先生此前曾是Z-Medica、Reliant Rehabilitation、Tandem Labs、American Optics、Global Physics Solutions、Spectrum Solutions和Arteriocyte Medical Systems的董事会成员。Schillinger先生也是医疗保健私募股权协会的现任董事会成员和哈佛商学院校友董事会的前任成员。
- Doug Schillinger,has served on Board of Directors since May 4, 2021. Mr. Schillinger joined DW Healthcare Partners in 2004 and is currently a Managing Director and oversees several of the firm's portfolio investments. Mr. Schillinger's investment, transaction and board experience include a broad array of healthcare service and medical devices including pharma services, diagnostics, medical tech products and devices, provider services, laboratory services, post-acute care, medical aesthetics, and telehealth. Before joining DW Healthcare Partners, Mr. Schillinger worked for Bain & Company and Accenture (previously Andersen Consulting). He is currently a board member of Public Partnerships Limited, Parnell Veterinary Pharmaceuticals, Aequor Healthcare Services, Chrysalis, CareXM, and Vets Plus Inc. Mr. Schillinger was previously a board member of Z-Medica, Reliant Rehabilitation, Tandem Labs, American Optics, Global Physics Solutions, Spectrum Solutions, and Arteriocyte Medical Systems. Mr. Schillinger is also a current board member of the Healthcare Private Equity Association and a former member of the Harvard Business School Alumni Board of Directors.
- Pedro Malha
-
Pedro Malha，于2021年9月至2025年9月期间担任在纽约证券交易所上市的全球医疗保健上市公司雅培的全球部门总裁兼公司高管。在重新加入雅培之前，Malha先生曾在齐默巴奥米特控股公司担任Worldwide Group总裁兼部门总裁，该公司是一家在纽约证券交易所上市的全球医疗器械上市公司，在2017年5月至2021年9月期间，他领导了多个业务部门的全球业务。从2008年到2016年，Malha先生在雅培担任过多个高级领导职务，包括部门副总裁，负责监督美洲和欧洲、中东和非洲地区的商业组织和战略职能。在Malha先生最初任职于雅培之前，他在强生工作了六年，这家公司是一家在纽约证券交易所上市的全球医疗保健上市公司，他在该公司的欧洲业务中担任的职务越来越重要。Malha先生拥有波士顿大学工商管理硕士学位和本特利大学理学学士学位。
Pedro Malha,served as Worldwide Division President and Corporate Officer of Abbott Laboratories, a publicly-traded global healthcare company listed on the New York Stock Exchange, from September 2021 to September 2025. Before rejoining Abbott Laboratories, Mr. Malha served as Worldwide Group President and Division President at Zimmer Biomet Holdings, Inc., a publicly-traded global medical device company listed on the New York Stock Exchange, where he led global operations across multiple business units from May 2017 to September 2021. From 2008 to 2016, Mr. Malha held several senior leadership roles at Abbott Laboratories, including Divisional Vice President, overseeing commercial organizations and strategic functions across the Americas and EMEA regions. Prior to Mr. Malha's original tenure with Abbott Laboratories, he spent six years at Johnson & Johnson, a publicly-traded global healthcare company listed on the New York Stock Exchange, where he held positions of increasing responsibility within its European operations. Mr. Malha holds a Master of Business Administration from Boston University and a Bachelor of Science from Bentley University. - Pedro Malha，于2021年9月至2025年9月期间担任在纽约证券交易所上市的全球医疗保健上市公司雅培的全球部门总裁兼公司高管。在重新加入雅培之前，Malha先生曾在齐默巴奥米特控股公司担任Worldwide Group总裁兼部门总裁，该公司是一家在纽约证券交易所上市的全球医疗器械上市公司，在2017年5月至2021年9月期间，他领导了多个业务部门的全球业务。从2008年到2016年，Malha先生在雅培担任过多个高级领导职务，包括部门副总裁，负责监督美洲和欧洲、中东和非洲地区的商业组织和战略职能。在Malha先生最初任职于雅培之前，他在强生工作了六年，这家公司是一家在纽约证券交易所上市的全球医疗保健上市公司，他在该公司的欧洲业务中担任的职务越来越重要。Malha先生拥有波士顿大学工商管理硕士学位和本特利大学理学学士学位。
- Pedro Malha,served as Worldwide Division President and Corporate Officer of Abbott Laboratories, a publicly-traded global healthcare company listed on the New York Stock Exchange, from September 2021 to September 2025. Before rejoining Abbott Laboratories, Mr. Malha served as Worldwide Group President and Division President at Zimmer Biomet Holdings, Inc., a publicly-traded global medical device company listed on the New York Stock Exchange, where he led global operations across multiple business units from May 2017 to September 2021. From 2008 to 2016, Mr. Malha held several senior leadership roles at Abbott Laboratories, including Divisional Vice President, overseeing commercial organizations and strategic functions across the Americas and EMEA regions. Prior to Mr. Malha's original tenure with Abbott Laboratories, he spent six years at Johnson & Johnson, a publicly-traded global healthcare company listed on the New York Stock Exchange, where he held positions of increasing responsibility within its European operations. Mr. Malha holds a Master of Business Administration from Boston University and a Bachelor of Science from Bentley University.
- Philippe Schaison
-
Philippe Schaison，目前担任生物化妆品公司Solt é go，Inc.的首席执行官和董事，自2018年起。在加入Solt é go之前，他于2017年至2018年担任医疗美容和美容激光公司Syneron Candela的首席执行官NA，并于2013年至2017年担任Allergan Aesthetic的总裁。Schaison博士自2020年起担任总部位于以色列的生物技术公司Raziel Therapeutics Ltd.的董事会主席，目前在多家其他生物医药公司董事会任职，包括自2019年以来的AIVITA Biomedical，Inc.；自2020年以来的Dyve Biosciences，Inc.；自2022年以来的miraDry，Inc.。Schaison博士在巴黎Hautes Etudes Commerciales获得工商管理硕士学位，在巴黎V Ren é Descartes大学获得药学博士学位。
Philippe Schaison,currently serves as the Chief Executive Officer and as a director of Soltégo, Inc., a bio-cosmetics company, since 2018. Prior to his role at Soltégo, he was Chief Executive Officer NA of Syneron Candela, a medical aesthetic and cosmetic laser company, from 2017 to 2018, and President of Allergan Aesthetic, from 2013 to 2017. Dr. Schaison has served as Chairman of the Board of Raziel Therapeutics Ltd., an Israeli-based biotechnology company, since 2020, and currently sits on a number of other biomedical company boards including AIVITA Biomedical, Inc. since 2019; Dyve Biosciences, Inc. since 2020; and miraDry, Inc. since 2022. Dr. Schaison earned an M.B.A. from Hautes Etudes Commerciales in Paris, and a Doctorate in Pharmacy from the Université Paris V René Descartes. - Philippe Schaison，目前担任生物化妆品公司Solt é go，Inc.的首席执行官和董事，自2018年起。在加入Solt é go之前，他于2017年至2018年担任医疗美容和美容激光公司Syneron Candela的首席执行官NA，并于2013年至2017年担任Allergan Aesthetic的总裁。Schaison博士自2020年起担任总部位于以色列的生物技术公司Raziel Therapeutics Ltd.的董事会主席，目前在多家其他生物医药公司董事会任职，包括自2019年以来的AIVITA Biomedical，Inc.；自2020年以来的Dyve Biosciences，Inc.；自2022年以来的miraDry，Inc.。Schaison博士在巴黎Hautes Etudes Commerciales获得工商管理硕士学位，在巴黎V Ren é Descartes大学获得药学博士学位。
- Philippe Schaison,currently serves as the Chief Executive Officer and as a director of Soltégo, Inc., a bio-cosmetics company, since 2018. Prior to his role at Soltégo, he was Chief Executive Officer NA of Syneron Candela, a medical aesthetic and cosmetic laser company, from 2017 to 2018, and President of Allergan Aesthetic, from 2013 to 2017. Dr. Schaison has served as Chairman of the Board of Raziel Therapeutics Ltd., an Israeli-based biotechnology company, since 2020, and currently sits on a number of other biomedical company boards including AIVITA Biomedical, Inc. since 2019; Dyve Biosciences, Inc. since 2020; and miraDry, Inc. since 2022. Dr. Schaison earned an M.B.A. from Hautes Etudes Commerciales in Paris, and a Doctorate in Pharmacy from the Université Paris V René Descartes.
- Stephen J. Fanning
-
Stephen J. Fanning，自2005年1月起担任总裁兼首席执行官；2006年7月起担任董事长；2001年8月至2005年1月间担任Ocular Sciences（一次性隐形眼镜制造商与分销商）的总裁兼首席执行官；此前，他在Johnson & Johnson任职逾25年，担任多个高管职位。他目前是一家私营企业的董事，该公司开发美学市场外部医疗设备。在过去的五年中，他也曾担任Isolagen（生物技术公司）的董事。他获得了Philadelphia大学的学士学位。
Stephen J. Fanning has been President and Chief Executive Officer since January 2005 and Chairman of the board of directors since July 2006. From August 2001 to January 2005 Mr. Fanning served as the President and Chief Executive Officer of Ocular Sciences, a manufacturer and distributor of disposable contact lenses. Previously, Mr. Fanning served in various senior executive positions at Johnson & Johnson for over 25 years. Mr. Fanning currently serves as a director of a privately held company that develops medical devices outside of the aesthetics market. Within the past five years, Mr. Fanning also served on the board of directors of Isolagen, a biotechnology company. Mr. Fanning received his B.S. degree from Philadelphia University. - Stephen J. Fanning，自2005年1月起担任总裁兼首席执行官；2006年7月起担任董事长；2001年8月至2005年1月间担任Ocular Sciences（一次性隐形眼镜制造商与分销商）的总裁兼首席执行官；此前，他在Johnson & Johnson任职逾25年，担任多个高管职位。他目前是一家私营企业的董事，该公司开发美学市场外部医疗设备。在过去的五年中，他也曾担任Isolagen（生物技术公司）的董事。他获得了Philadelphia大学的学士学位。
- Stephen J. Fanning has been President and Chief Executive Officer since January 2005 and Chairman of the board of directors since July 2006. From August 2001 to January 2005 Mr. Fanning served as the President and Chief Executive Officer of Ocular Sciences, a manufacturer and distributor of disposable contact lenses. Previously, Mr. Fanning served in various senior executive positions at Johnson & Johnson for over 25 years. Mr. Fanning currently serves as a director of a privately held company that develops medical devices outside of the aesthetics market. Within the past five years, Mr. Fanning also served on the board of directors of Isolagen, a biotechnology company. Mr. Fanning received his B.S. degree from Philadelphia University.
- Brenton L. Saunders
-
Brenton L. Saunders，自2010三月起担任博士伦首席执行官和董事。此前，2003-2010，他担任先灵葆雅的高级执行官，最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并，及160亿美元收购欧加农生物公司这两项并购业务，他都是负责人。在加入先灵葆雅之前，2000-2003，他担任普华永道的董事，及合规经营咨询部的负责人。在这之前，1998-1999，他是Coventry Health Carer的首席风险官；1995，他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯，担任首席合规官。除了担任博士伦董事，他还在ElectroCore LLC，the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会，美国药物研究和制造商协会，和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位，天普大学商学院工商管理硕士学位，天普大学法学院法学博士学位。
Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business. - Brenton L. Saunders，自2010三月起担任博士伦首席执行官和董事。此前，2003-2010，他担任先灵葆雅的高级执行官，最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并，及160亿美元收购欧加农生物公司这两项并购业务，他都是负责人。在加入先灵葆雅之前，2000-2003，他担任普华永道的董事，及合规经营咨询部的负责人。在这之前，1998-1999，他是Coventry Health Carer的首席风险官；1995，他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯，担任首席合规官。除了担任博士伦董事，他还在ElectroCore LLC，the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会，美国药物研究和制造商协会，和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位，天普大学商学院工商管理硕士学位，天普大学法学院法学博士学位。
- Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
高管简历
中英对照 | 中文 | 英文- Sheri Lewis
Sheri Lewis于2024年4月起受雇于Skin Health Systems，担任首席供应链和运营官。Lewis女士于2021年1月至2024年3月期间受聘于Avantor科学公司担任全球供应链运营执行副总裁，此前曾在美敦力和霍尼韦尔 Inc.担任多个运营、供应链和分销职位。Lewis女士拥有康考迪亚大学组织管理文学学士学位，目前担任威斯康星大学供应链顾问委员会成员，此前曾担任明尼苏达大学供应链顾问委员会成员。
Sheri Lewis was employed from April 2024 as Chief Supply Chain and Operations Officer of Skin Health Systems. Ms. Lewis was employed as Executive Vice President, Global Supply Chain Operations, of Avantor Sciences from January 2021 until March 2024 and previously served in multiple operations, supply chain and distribution positions with Medtronic and Honeywell Inc. Ms. Lewis holds a Bachelor of Arts degree in Organizational Management from Concordia University, currently serves as a member of the Supply Chain Advisory Board at the University of Wisconsin and previously served as a member of the Supply Chain Advisory Board at the University of Minnesota.- Sheri Lewis于2024年4月起受雇于Skin Health Systems，担任首席供应链和运营官。Lewis女士于2021年1月至2024年3月期间受聘于Avantor科学公司担任全球供应链运营执行副总裁，此前曾在美敦力和霍尼韦尔 Inc.担任多个运营、供应链和分销职位。Lewis女士拥有康考迪亚大学组织管理文学学士学位，目前担任威斯康星大学供应链顾问委员会成员，此前曾担任明尼苏达大学供应链顾问委员会成员。
- Sheri Lewis was employed from April 2024 as Chief Supply Chain and Operations Officer of Skin Health Systems. Ms. Lewis was employed as Executive Vice President, Global Supply Chain Operations, of Avantor Sciences from January 2021 until March 2024 and previously served in multiple operations, supply chain and distribution positions with Medtronic and Honeywell Inc. Ms. Lewis holds a Bachelor of Arts degree in Organizational Management from Concordia University, currently serves as a member of the Supply Chain Advisory Board at the University of Wisconsin and previously served as a member of the Supply Chain Advisory Board at the University of Minnesota.
- Michael Monahan
Michael Monahan，自2023年8月10日起担任公司首席财务官。在获得任命之前，Monahan先生于2020年8月至2022年7月期间担任Casper Sleep Inc.（一家上市的睡眠产品公司，之前在纽约证券交易所上市）的首席财务官。从2019年6月至2019年10月，Monahan先生担任HEXO Corp.的首席财务官，该公司是一家上市包装消费品公司，以前在纽约证券交易所和多伦多证券交易所上市。从2013年5月至2019年6月，Monahan先生担任Nutrisystem, Inc.，Inc.的首席财务官，该公司是一家上市体重管理产品公司，之前在纳斯达克 Stock Market LLC上市。2009年1月至2013年5月，Monahan先生在PetroChoice Holdings，Inc.（一家工业、商业和乘用车润滑油分销商）担任首席财务官。Monahan先生获得了维拉诺瓦大学的学士学位，并获得了芝加哥大学的工商管理硕士学位。
Michael Monahan,has served as the Company's Chief Financial Officer since August 10, 2023. Prior to his appointment, Mr. Monahan served as the Chief Financial Officer for Casper Sleep Inc., a publicly-traded sleep products company that was formerly listed on the New York Stock Exchange, from August 2020 to July 2022. From June 2019 to October 2019, Mr. Monahan served as the Chief Financial Officer for HEXO Corp., a publicly-traded consumer packaged goods company formerly listed on the New York Stock Exchange and the Toronto Stock Exchange. From May 2013 to June 2019, Mr. Monahan served as the Chief Financial Officer of Nutrisystem, Inc., a publicly-traded weight management products company formerly listed on The Nasdaq Stock Market LLC. From January 2009 to May 2013, Mr. Monahan served as the Chief Financial Officer of PetroChoice Holdings, Inc., a distributor of industrial, commercial and passenger car lubricants. Mr. Monahan received his B.A. from Villanova University, and received his M.B.A. from the University of Chicago.- Michael Monahan，自2023年8月10日起担任公司首席财务官。在获得任命之前，Monahan先生于2020年8月至2022年7月期间担任Casper Sleep Inc.（一家上市的睡眠产品公司，之前在纽约证券交易所上市）的首席财务官。从2019年6月至2019年10月，Monahan先生担任HEXO Corp.的首席财务官，该公司是一家上市包装消费品公司，以前在纽约证券交易所和多伦多证券交易所上市。从2013年5月至2019年6月，Monahan先生担任Nutrisystem, Inc.，Inc.的首席财务官，该公司是一家上市体重管理产品公司，之前在纳斯达克 Stock Market LLC上市。2009年1月至2013年5月，Monahan先生在PetroChoice Holdings，Inc.（一家工业、商业和乘用车润滑油分销商）担任首席财务官。Monahan先生获得了维拉诺瓦大学的学士学位，并获得了芝加哥大学的工商管理硕士学位。
- Michael Monahan,has served as the Company's Chief Financial Officer since August 10, 2023. Prior to his appointment, Mr. Monahan served as the Chief Financial Officer for Casper Sleep Inc., a publicly-traded sleep products company that was formerly listed on the New York Stock Exchange, from August 2020 to July 2022. From June 2019 to October 2019, Mr. Monahan served as the Chief Financial Officer for HEXO Corp., a publicly-traded consumer packaged goods company formerly listed on the New York Stock Exchange and the Toronto Stock Exchange. From May 2013 to June 2019, Mr. Monahan served as the Chief Financial Officer of Nutrisystem, Inc., a publicly-traded weight management products company formerly listed on The Nasdaq Stock Market LLC. From January 2009 to May 2013, Mr. Monahan served as the Chief Financial Officer of PetroChoice Holdings, Inc., a distributor of industrial, commercial and passenger car lubricants. Mr. Monahan received his B.A. from Villanova University, and received his M.B.A. from the University of Chicago.
- Ron Menezes
Ron Menezes，自2024年10月15日起担任公司首席营收官。在获得任命之前，Menezes先生于2020年11月至2024年6月期间担任Sientra, Inc.的董事、总裁兼首席执行官，该公司是一家上市的医美产品公司，之前在纳斯达克上市。在加入Sientra, Inc.之前，Menezes先生于2017年8月至2020年11月期间担任Almirall U.S. – Dermatology的总裁兼总经理。在加入Almirall之前，Menezes先生于2016年至2017年8月期间担任专业制药公司Assertio Therapeutics, Inc.（前身为Depomed Inc.）的销售和运营副总裁。此前，Menezes先生曾在Allergan PLC、雅培、Astellas Pharma Inc.、辉瑞 Inc.和Eli，Lilly and Co.担任过一系列领导职务。Menezes先生还担任Diverse Biotech，Inc.的董事，该公司是一家专门从事肿瘤药物发现的公司。Menezes先生拥有杨百翰大学国际商务学士学位。
Ron Menezes,has served as the Company's Chief Revenue Officer since October 15, 2024. Prior to his appointment, Mr. Menezes served as a director, President and Chief Executive Officer of Sientra, Inc., a publicly traded medical aesthetic products company that was formerly listed on NASDAQ, from November 2020 through June 2024. Prior to joining Sientra, Inc., Mr. Menezes served as President and General Manager for Almirall U.S. – Dermatology from August 2017 until November 2020. Prior to joining Almirall, Mr. Menezes served as Vice President of Sales and Operations of Assertio Therapeutics, Inc. (formerly Depomed Inc.), a specialty pharmaceutical company, from 2016 until August 2017. Formerly, Mr. Menezes served in a series of leadership roles at Allergan plc, Abbott Laboratories, Astellas Pharma Inc., Pfizer Inc. and Eli, Lilly and Co. Mr. Menezes also serves as a director of Diverse Biotech, Inc., a company specializing in oncology drug discovery. Mr. Menezes holds a B.S. in International Business from Brigham Young University.- Ron Menezes，自2024年10月15日起担任公司首席营收官。在获得任命之前，Menezes先生于2020年11月至2024年6月期间担任Sientra, Inc.的董事、总裁兼首席执行官，该公司是一家上市的医美产品公司，之前在纳斯达克上市。在加入Sientra, Inc.之前，Menezes先生于2017年8月至2020年11月期间担任Almirall U.S. – Dermatology的总裁兼总经理。在加入Almirall之前，Menezes先生于2016年至2017年8月期间担任专业制药公司Assertio Therapeutics, Inc.（前身为Depomed Inc.）的销售和运营副总裁。此前，Menezes先生曾在Allergan PLC、雅培、Astellas Pharma Inc.、辉瑞 Inc.和Eli，Lilly and Co.担任过一系列领导职务。Menezes先生还担任Diverse Biotech，Inc.的董事，该公司是一家专门从事肿瘤药物发现的公司。Menezes先生拥有杨百翰大学国际商务学士学位。
- Ron Menezes,has served as the Company's Chief Revenue Officer since October 15, 2024. Prior to his appointment, Mr. Menezes served as a director, President and Chief Executive Officer of Sientra, Inc., a publicly traded medical aesthetic products company that was formerly listed on NASDAQ, from November 2020 through June 2024. Prior to joining Sientra, Inc., Mr. Menezes served as President and General Manager for Almirall U.S. – Dermatology from August 2017 until November 2020. Prior to joining Almirall, Mr. Menezes served as Vice President of Sales and Operations of Assertio Therapeutics, Inc. (formerly Depomed Inc.), a specialty pharmaceutical company, from 2016 until August 2017. Formerly, Mr. Menezes served in a series of leadership roles at Allergan plc, Abbott Laboratories, Astellas Pharma Inc., Pfizer Inc. and Eli, Lilly and Co. Mr. Menezes also serves as a director of Diverse Biotech, Inc., a company specializing in oncology drug discovery. Mr. Menezes holds a B.S. in International Business from Brigham Young University.
- Pedro Malha
Pedro Malha，于2021年9月至2025年9月期间担任在纽约证券交易所上市的全球医疗保健上市公司雅培的全球部门总裁兼公司高管。在重新加入雅培之前，Malha先生曾在齐默巴奥米特控股公司担任Worldwide Group总裁兼部门总裁，该公司是一家在纽约证券交易所上市的全球医疗器械上市公司，在2017年5月至2021年9月期间，他领导了多个业务部门的全球业务。从2008年到2016年，Malha先生在雅培担任过多个高级领导职务，包括部门副总裁，负责监督美洲和欧洲、中东和非洲地区的商业组织和战略职能。在Malha先生最初任职于雅培之前，他在强生工作了六年，这家公司是一家在纽约证券交易所上市的全球医疗保健上市公司，他在该公司的欧洲业务中担任的职务越来越重要。Malha先生拥有波士顿大学工商管理硕士学位和本特利大学理学学士学位。
Pedro Malha,served as Worldwide Division President and Corporate Officer of Abbott Laboratories, a publicly-traded global healthcare company listed on the New York Stock Exchange, from September 2021 to September 2025. Before rejoining Abbott Laboratories, Mr. Malha served as Worldwide Group President and Division President at Zimmer Biomet Holdings, Inc., a publicly-traded global medical device company listed on the New York Stock Exchange, where he led global operations across multiple business units from May 2017 to September 2021. From 2008 to 2016, Mr. Malha held several senior leadership roles at Abbott Laboratories, including Divisional Vice President, overseeing commercial organizations and strategic functions across the Americas and EMEA regions. Prior to Mr. Malha's original tenure with Abbott Laboratories, he spent six years at Johnson & Johnson, a publicly-traded global healthcare company listed on the New York Stock Exchange, where he held positions of increasing responsibility within its European operations. Mr. Malha holds a Master of Business Administration from Boston University and a Bachelor of Science from Bentley University.- Pedro Malha，于2021年9月至2025年9月期间担任在纽约证券交易所上市的全球医疗保健上市公司雅培的全球部门总裁兼公司高管。在重新加入雅培之前，Malha先生曾在齐默巴奥米特控股公司担任Worldwide Group总裁兼部门总裁，该公司是一家在纽约证券交易所上市的全球医疗器械上市公司，在2017年5月至2021年9月期间，他领导了多个业务部门的全球业务。从2008年到2016年，Malha先生在雅培担任过多个高级领导职务，包括部门副总裁，负责监督美洲和欧洲、中东和非洲地区的商业组织和战略职能。在Malha先生最初任职于雅培之前，他在强生工作了六年，这家公司是一家在纽约证券交易所上市的全球医疗保健上市公司，他在该公司的欧洲业务中担任的职务越来越重要。Malha先生拥有波士顿大学工商管理硕士学位和本特利大学理学学士学位。
- Pedro Malha,served as Worldwide Division President and Corporate Officer of Abbott Laboratories, a publicly-traded global healthcare company listed on the New York Stock Exchange, from September 2021 to September 2025. Before rejoining Abbott Laboratories, Mr. Malha served as Worldwide Group President and Division President at Zimmer Biomet Holdings, Inc., a publicly-traded global medical device company listed on the New York Stock Exchange, where he led global operations across multiple business units from May 2017 to September 2021. From 2008 to 2016, Mr. Malha held several senior leadership roles at Abbott Laboratories, including Divisional Vice President, overseeing commercial organizations and strategic functions across the Americas and EMEA regions. Prior to Mr. Malha's original tenure with Abbott Laboratories, he spent six years at Johnson & Johnson, a publicly-traded global healthcare company listed on the New York Stock Exchange, where he held positions of increasing responsibility within its European operations. Mr. Malha holds a Master of Business Administration from Boston University and a Bachelor of Science from Bentley University.